Case-only analysis of treatment-covariate interactions in clinical trials

Biometrics

Volumn 62, Issue 3, 2006, Pages 769-776

  Vittinghoff, E ^a   Bauer, D C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Case cohort; Case only; Randomized trials; Subgroup analysis

Indexed keywords

BIOMETRICS;

CASE-COHORT; CASE-CONTROL; CASE-ONLY; CLINICAL TRIAL; COVARIATES; PHARMACOGENOMICS; PRE-TREATMENTS; RANDOMIZED TRIAL; RESEARCH FIELDS; SUBGROUP ANALYSE;

CLINICAL RESEARCH;

COVARIANCE ANALYSIS; DRUG; RESEARCH WORK;

ANALYTIC METHOD; ARTICLE; ASSAY; CASE COHORT ANALYSIS; CASE ONLY ANALYSIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; RELIABILITY; SIMULATION; VARIANCE;

EID: 33748787405     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2006.00511.x     Document Type: Article

References (14)

1. Albert, P. S., Ratnasinghe, D., Tangrea, J., and Wacholder, S. (2001). Limitations of the case-only design for identifying gene-environment interactions. American Journal of Epidemiology 154, 687-693.
2. Armstrong, B. G. (2003). Fixed factors that modify the effects of time-varying factors: Applying the case-only approach. Epidemiology 14, 467-472.
3. Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., and Cummings, S. R. (2000). Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. Journal of Clinical Endocrinology and Metabolism 85, 4118-4124.
4. Carroll, R. J., Ruppert, D., and Stefanski, L. A. (1995). Measurement Error in Nonlinear Models. New York, London: Chapman & Hall.
5. Chen, K. (2001). Generalized case-cohort sampling. Journal of the Royal Statistical Society, Series B 63, 791-809.
6. Cummings, S. R., Duong, T., Kenyon, E., Cauley, J. A., Whitehead, M. A., and Krueger, K. A. (2002). Multiple Outcomes of Raloxifene Evaluation (MORE) Trial: Serum estradiol level and risk of breast cancer during treatment with raloxifene. Journal of the American Medical Association 287, 216-220.
7. Furberg, C. D., Vittinghoff, E., Davidson, M., Herrington, D. M., Simon, J. A., Wenger, N. K., and Hulley, S. (2002). Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons learned. Circulation 105, 917-922.
8. Greenland, S. (1999). A unified approach to the analysis of case-distribution (case-only) studies. Statistics in Medicine 18, 1-15.
9. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., and Vittinghoff, E. (1998). Randomized trial of estrogen plus progestin for secondary prevention of heart disease in postmenopausal women. Journal of the American Medical Association 280, 605-613.
10. Lin, D. Y. and Wei, L. J. (1989). The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association 84, 1074-1078.
11. Looker, A. C., Bauer, D. C., Chesnut, C. H., Gundberg, C. M., Hochberg, M. C., Klee, G., Kleerekoper, M., Watts, N. B., and Bell, N. H. (2000). Clinical use of biochemical bone markers of bone remodeling: Current status and future directions. Osteoporosis International 11, 467-480.
12. Prentice, R. L. (1986a). A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1-11.
13. Prentice, R. L. (1986b). On the design of synthetic case-control studies. Biometrics 42, 301-310.
14. Self, S. G., Longton, G., Kopecky, K. J., and Liang, K. Y. (1991). On estimating HLA/disease association with application to a study of aplastic anemia. Biometrics 47, 53-61.